Learning from viruses: The necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong anti-tumor immune responses

Pharmaceutical Research

Volumn 24, Issue 9, 2007, Pages 1645-1652

  Cui, Zhengrong ^a   Le, Uyen M ^a   Qiu, Fu ^a   Shaker, Dalia S ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

CTL; Intracellular dsRNA; TLR3; Tumor immunotherapy

Indexed keywords

DOUBLE STRANDED RNA; POLYINOSINIC POLYCYTIDYLIC ACID; TUMOR VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER THERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; UTERINE CERVIX CANCER; VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; IMMUNIZATION; MICE; MICE, INBRED C57BL; NECROSIS; NEOPLASMS, EXPERIMENTAL; POLY I-C; RNA, DOUBLE-STRANDED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34547635430     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9293-5     Document Type: Article

References (37)

1. H. E. Kaufman, E. D. Ellison, and S. R. Waltman. Double-stranded RNA, an interferon inducer, in herpes simplex keratitis. Am. J. Ophthalmol. 68:486-491 (1969).
2. G. R. Foster, and N. B. Finter. Are all type I human interferons equivalent? J. Viral Hepatitis 5:143-152 (1998).
3. M. Chawla-Sarkar, D. J. Lindner, Y. F. Liu, B. R. Williams, G. C. Sen, R. H. Silverman, and E. C. Borden. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8:237-249 (2003).
4. L. G. Guidotti, and F. V. Chisari. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19:65-91 (2001).
5. G. R. Stark, I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264 (1998).
6. Y. L. Yang, L. F. Reis, J. Pavlovic, A. Aguzzi, R. Schafer, A. Kumar, B. R. Williams, M. Aguet, and C. Weissmann. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 14:6095-6106 (1995).
7. R. Herman and S. Baron. Immunologic-mediated protection of Trypanosoma congolense-infected mice by polyribonucleotides. J. Protozool. 18:661-666 (1971).
8. J. H. Park, and S. Baron. Herpetic keratoconjunctivitis: therapy with synthetic double-stranded RNA. Science 162:811-813 (1968).
9. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732-738 (2001).
10. R. M. Verdijk, T. Mutis, B. Esendam, J. Kamp, C. J. Melief, A. Brand, and E. Goulmy. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J. Immunol. 163:57-61 (1999).
11. K. N. Schmidt, B. Leung, M. Kwong, K. A. Zarember, S. Satyal, T. A. Navas, F. Wang, and P. J. Godowski. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J. Immunol. 172:138-143 (2004).
12. S. Sivori, M. Falco, M. Della Chiesa, S. Carlomagno, M. Vitale, L. Moretta, and A. Moretta. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 101:10116-10121 (2004).
13. A. E. Gelman, J. Zhang, Y. Choi, and L. A. Turka. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J. Immunol. 172:6065-6073 (2004).
14. M. L. Salem, A. N. Kadima, D. J. Cole, and W. E. Gillanders. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 28:220-228 (2005).
15. Z. R. Cui, and F. Qiu. CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted epitope. J. Immunother. 30:180-189 (2007).
16. F. Henry, O. Boisteau, L. Bretaudeau, B. Lieubeau, K. Meflah, and M. Gregoire. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 59:3329-3332 (1999).
17. A. Le Bon, N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D. F. Tough. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009-1015 (2003).
18. J. Frappa, P. Trotemann, Y. Beaudry, and R. Fontanges. Production of IFN beta with human fibroblasts in monolayer cultures. Comparative studies of induction with virus (NDV) and synthetic polynucleotides (poly I-poly C). Dev. Biol. Stand. 50:185-192 (1981).
19. P. B. Sehgal, and A. D. Sagar. Heterogeneity of poly(I) x poly(C)-induced human fibroblast interferon mRNA species. Nature 288:95-97 (1980).
20. O. Schulz, S. S. Diebold, M. Chen, T. I. Naslund, M. A. Nolte, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljestrom, and C. Reis e Sousa. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433:887-892 (2005).
21. G. J. Fernando, V. Khammanivong, G. R. Leggatt, W. J. Liu, and I. H. Frazer. The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. Eur. J. Immunol. 32:1541-1549 (2002).
22. G. J. Fernando, T. J. Stewart, R. W. Tindle, and I. H. Frazer. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J. Immunol. 161:2421-2427 (1998).
23. M. Salio, and V. Cerundolo. Viral immunity: cross-priming with the help of TLR3. Curr. Biol. 15:R336-R339 (2005).
24. K. Y. Lin, F. G. Guarnieri, K. F. Staveley-O'Carroll, H. I. Levitsky, J. T. August, D. M. Pardoll, and T. C. Wu. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26 (1996).
25. P. Hwu, J. C. Yang, R. Cowherd, J. Treisman, G. E. Shafer, Z. Eshhar, and S. A. Rosenberg. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55:3369-3373 (1995).
26. Z. Cui, and F. Qiu. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol. Immunother. 55:1267-1279 (2006).
27. N. Fujita, H. Kagamu, H. Yoshizawa, K. Itoh, H. Kuriyama, N. Matsumoto, T. Ishiguro, J. Tanaka, E. Suzuki, H. Hamada, and F. Gejyo. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J. Immunol. 167:5678-5688 (2001).
28. H. B. Levy, G. Baer, S. Baron, C. E. Buckler, C. J. Gibbs, M. J. Iadarola, W. T. London, and J. Rice. A modified polyriboinosinic- polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 132:434-9 (1975).
29. W. E. Houston, C. L. Crabbs, E. L. Stephen, and H. B. Levy. Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect. Immun. 14:318-319 (1976).
30. A. Michael, G. Ball, N. Quatan, F. Wushishi, N. Russell, J. Whelan, P. Chakraborty, D. Leader, M. Whelan, and H. Pandha. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11:4469-4478 (2005).
31. A. A. Green, C. Pratt, R. G. Webster, and K. Smith. Immunotherapy of osteosarcoma patients with virus-modified tumor cells. Ann. N. Y. Acad. Sci. 277:396-411 (1976).
32. P. Hersey, A. S. Coates, W. H. McCarthy, J. F. Thompson, R. W. Sillar, R. McLeod, P. G. Gill, B. J. Coventry, A. McMullen, H. Dillon, and R. J. Simes. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol. 20:4181-4190 (2002).
33. M. K. Wallack, M. Sivanandham, C. M. Balch, M. M. Urist, K. I. Bland, D. Murray, W. A. Robinson, L. Flaherty, J. M. Richards, A. A. Bartolucci, and L. Rosen. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. 187:69-77, 77-79 (discussion) (1998).
34. G. P. Lampson, A. A. Tytell, A. K. Field, M. M. Nemes, and M. R. Hilleman. Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc. Natl. Acad. Sci. U. S. A. 58:782-789 (1967).
35. P. J. Farrell, G. C. Sen, M. F. Dubois, L. Ratner, E. Slattery, and P. Lengyel. Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc. Natl. Acad. Sci. U. S. A. 75:5893-5897 (1978).
36. E. F. Meurs, J. Galabru, G. N. Barber, M. G. Katze, and A. G. Hovanessian. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A. 90:232-236 (1993).
37. A. Shir, M. Ogris, E. Wagner, and A. Levitzki. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PloS. Med. 3:e6 (2006).